The FDA has approved Spinraza, the first drug to treat patients with spinal muscular atrophy, a disease that can kill infants before they turn 2. Biogen, which is licensing it from Ionis, said one dose will cost $125,000--equaling up to $750,000 to cover the the first year, and about $375,000 annually after that. Patients presumably take it the rest of their lives. The pricing could put it in the cross hairs of lawmakers and perhaps discourage insurers from covering it.
read more